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a  b  s  t  r  a  c  t
The  aim  of this  study  was  to calculate  the  costs  of  the current  initial  treatment  of acute  myeloid  leukemia.
Resource  use  was  collected  for  202 patients  who  started  with  intensive  chemotherapy  in 2008  or  2009.
The  costs  of  the  ﬁrst  induction  course  were  signiﬁcantly  higher  than  the  costs  of the  second  induction
course.  Allogeneic  transplantation  from  a matched  unrelated  donor  was  signiﬁcantly  more  expensive
than  the other  consolidation  treatments.  In-hospital  stay  was  the  major  cost  driver  in  the treatment  of
AML.  Research  regarding  possibilities  of  achieving  the  same  or better  health  outcome  with  lower  costs
is warranted.eywords:
osts
cute myeloid leukemia
nduction treatment
onsolidation treatment
ollow-up
© 2012 Elsevier Ltd. Open access under the Elsevier OA license.ost components
. Introduction
Acute myeloid leukemia (AML) is an aggressive disease which
equires intensive treatment. Treatment of AML generally consists
f several induction chemotherapy courses to induce complete
emission (CR). Induction treatment is followed by consolidation
reatment consisting of high-dose chemotherapy or autologous
r allogeneic hematopoietic stem cell transplantation (HSCT) for
atients younger than 60–65 years of age. Stem cell sources of
llogeneic HSCT are threefold: HLA-identical sibling, matched unre-
ated donor (MUD) or umbilical cord blood (UCB) [1].  The choice of
onsolidation treatment depends on the patient’s risk of relapse
nd treatment-related mortality [2].
Insight into the treatment costs is an essential requirement for
dequate reimbursement of treatment. In addition, cost calcula-
ions are required as input for cost-effectiveness analyses of (new)
reatments. The cost-effectiveness factor will become increas-
ngly important due to rising health care expenditures in Western
∗ Corresponding author at: iMTA/iBMG, Erasmus Universiteit Rotterdam, PO Box
738, 3000 DR Rotterdam, The Netherlands. Tel.: +31 10 408 9763;
ax: +31 10 4089081.
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Open access under the Elsevier OA license.countries [3].  A few studies in the 90s and early 2000s have calcu-
lated the total costs of AML  treatment [4–6]. However, treatment
strategies have changed dramatically [7–10],  and an update of the
treatment costs is therefore essential. The aims of this study were
to gain insight into the current treatment costs and the different
cost components of the total treatment costs.
2. Materials and methods
2.1. Patients
All adult patients diagnosed with de novo primary or secondary AML  who
started with induction chemotherapy in 2008 or 2009 in three university hospitals
in  the Netherlands were included in this study. Patients with acute promyelocytic
leukemia (APL) were excluded because the number of patients was small and these
patients were treated differently. Data were collected from diagnosis until relapse,
death or last day of registration (June 2011).
2.2. Treatment
The initial treatment of AML  was distinguished in three treatment phases: induc-
tion treatment, consolidation treatment and follow-up. Induction treatment started
at  the day of diagnosis. Two different treatment protocols were used based on the
patient’s age. Younger patients (less than 65 years) received induction and consol-
idation treatment. Induction treatment consisted of cytarabine and idarubicin in
the ﬁrst course and cytarabine and amsacrine in the second course. Five different
consolidation treatments were administered: high-dose chemotherapy, autologous
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Table  1
Patients included in the different treatment phases.
All patients “Younger age” protocol “Older age” protocol
Induction course 1 202 145 57
Induction course 2 167 127 40
Consolidation treatment 126 126 –
High dose chemotherapy 47 47 –
Autologous SCT 18 18 –
Allogeneic SCT from sibling 35 35 –
Allogeneic SCT from MUD  21 21 –
Cord blood transplantation 5 5 –
Follow-up (1 year) 128 101 27
After induction treatment 27 – 27
After high dose chemotherapy 31 31 –
After autologous HSCT 16 16 –
After allogeneic HSCT from sibling 31 31 –
After allogeneic HSCT from MUD  19 19 –
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SCT: hematopoietic stem cell transplantation; MUD: matched unrelated donor.
SCT, allogeneic HSCT from a sibling donor, allogeneic HSCT from a MUD  and UCB
ransplantation. The choice of treatment depended on the patient’s risk of relapse,
erformance status and the availability of an HLA-identical donor. Older patients
eceived induction treatment consisting of cytarabine and daunorubicin in the ﬁrst
ourse and cytarabine in the second course. In both age groups, the second induction
ourse was administered to all patients, irrespective of achievement of a CR after
he ﬁrst course. The second induction course started the day after discharge for the
rst course. In case of a continuous hospitalization, the second course started on the
ay that cytarabine was given as part of the second course. Consolidation treatment
tarted on the day after discharge for the second induction course. Follow-up started
2  days after induction treatment in older patients and 42 days after consolidation
reatment in younger patients. Follow-up was set at 1 year or ended at the date of
elapse or death.
.3. Cost calculation
The microcosting method was used to calculate the direct hospital treatment
osts of AML. All medical resource use related to the treatment of AML and its
omplications was collected and multiplied by the unit cost of each resource use.
Resource use was derived from electronic patient charts and hospital informa-
ion systems used for ﬁnancial claims. The hospital information systems contained
atient-speciﬁc information regarding in-hospital stay, outpatient visits, daycare
isits, intensive care, laboratory tests, radiology and administration of blood prod-
cts. Medication use was  derived from electronic patient charts for a random
election of patients (10% of all patients). This selection included both younger and
lder patients.
Unit prices of laboratory tests, radiology and other hospital activities were
erived from national tariffs deﬁned by the Dutch Health Authority [11]. Refer-
nce unit prices were used for outpatient visits (D 148), daycare treatment (D 224),
n-hospital stay (D 712), intensive care days (D 2211) and blood products [12,13].
nit  prices of medications were derived from the Pharmaceutical Compass (Z-index
010). Unit prices of HLA-typing and donor search were obtained from Blommestein
t al. [14]. All unit prices included both capital and labor costs.
Costs were subcategorized into several cost groups: in-hospital stay, hospital
isits, diagnostic procedures, medication, blood products, radiation, HLA-typing and
onor search. Intensive care costs were included in the costs of in-hospital stay. Hos-
ital visits consisted of daycare treatment, outpatient visits, emergency unit visits
nd other consults. Diagnostic procedures consisted of laboratory tests, radiology
nd other activities.
Follow-up data were not always available for 1 year, because only patients diag-
osed in 2008 or 2009 were included in this study in order to calculate current
reatment costs. If follow-up data were available for at least 100 days in patients
live  without relapse, the costs were extrapolated to 1 year based on the average
osts per day.
Missing values were imputed according to the average costs per in-hospital day
uring chemotherapy and transplantation. During follow-up, missing values were
mputed according to the average costs per day spent in the hospital, including
utpatient visits and daycare treatment. All costs were based on Euro 2010 cost data.
here necessary, costs were updated to 2010 according to the national consumer
rice index [15].
.4. Statistical analysisMann–Whitney tests were used to test for signiﬁcant differences in costs,
n-hospital stay and treatment duration between treatment protocols, induction
ourses and consolidation treatments. A probability level <0.05 was considered
igniﬁcant. All analyses were performed using Microsoft Excel 2003 and SPSS 17.0.4 –
3. Results
3.1. Patients
In total, 202 patients were included in this study, of which 145
were treated according to the younger age protocol (Table 1). A sec-
ond induction course was  given to 127 (88%) younger and 40 (70%)
older adults. Consolidation treatment was  given to 126 patients.
A few patients (N = 8) received an allogeneic HSCT or UCB trans-
plantation after only one induction course. Most patients received
high-dose chemotherapy (N = 47) as consolidation treatment. Suf-
ﬁcient follow-up data were available for 101 (70%) younger and 27
(47%) older adults.
3.2. Induction treatment
The average costs of the two  induction courses were D 46,807
for the ﬁrst course and D 42,395 for the second course (Table 2).
Although the ﬁrst induction course was signiﬁcantly shorter than
the second course, the total costs of the ﬁrst course were sig-
niﬁcantly higher. This difference was  mainly related to higher
costs of diagnostic procedures as costs of diagnosis were included
in the ﬁrst course. In addition, blood products and medication
costs were signiﬁcantly higher during the ﬁrst course. Although
the chemotherapy dose was higher in the second course, the
chemotherapy costs were lower due to the lower unit price of the
anthracycline used in the second course. Costs of hospital visits
were signiﬁcantly lower in the ﬁrst course. In-hospital stay did not
differ signiﬁcantly between the two  courses. On average patients
were hospitalized 33.7 days during the ﬁrst induction course and
34.1 days during the second course.
Not all patients received both induction courses. The majority
of the patients who did not receive the second course were worse
off as they died during the ﬁrst course or were too ill to continue
intensive treatment. Although patients receiving only one induc-
tion course were worse off, no signiﬁcant difference in the total
costs of the ﬁrst induction course were found between patients
receiving a second course or not (data not shown).
The total costs of the second induction course were signiﬁcantly
higher in older patients compared to younger patients. However,
the duration of the second course was signiﬁcantly longer in older
patients; in fact, the total costs per treatment day did not differ sig-
niﬁcantly between the two  age groups. No signiﬁcant differences
in total costs of the ﬁrst induction course were found between
the two  age groups. In both induction courses, the chemother-
apy costs were signiﬁcantly higher in younger patients, while the
costs of other medications were signiﬁcantly lower. Duration of
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Table 2
Costs of induction treatment (in 2010 Euros, 1 Euro = $1.3257 [16]).
All patients “Older” patients “Younger” patients
Course 1
(N = 202)
Course 2
(N = 167)
Course 1
(N = 57)
Course 2
(N = 40)
Course 1
(N = 145)
Course 2
(N = 127)
Average time (days) 44* 60 48* 85† 42* 52
Mean  costs
(SE)
In-hospital stay 24,333
(575)
24,837
(729)
24,551
(1210)
25,622
(1231)
24,247
(647)
24,589
(878)
Hospital visits 342*
(29)
586
(58)
443*,†
(66)
1160*,†
(158)
302
(30)
405
(49)
Diagnostic activities 8443*
(227)
5583
(247)
8704*
(408)
6013†
(370)
8341*
(273)
5448
(303)
Chemotherapy 1520*
(250)
1354
(138)
366*,†
(32)
766*,†
(40)
1974*
(67)
1539
(95)
Other  medication 5273*
(176)
4006
(189)
6873*,†
(433)
4982*,†
(380)
4645*
(149)
3698
(218)
Blood  products 6895*
(285)
6029
(341)
6547
(445)
7067
(764)
7032*
(356)
5702
(378)
Total  mean costs
(SE)
46,807*
(1076)
42,395
(1362)
47,483
(2113)
45,610†
(2463)
46,541*
(1251)
41,382
(1609)
Median costs 43,355 36,827 42,749 43,638 43,411 35,647
SE: standard error.
h
g
s
t
3
h
f
g
T
C
H* Signiﬁcantly different from the costs in the second induction course (p < 0.05).
† Signiﬁcantly different from the induction costs of “younger” patients (p < 0.05).
ospitalization did not differ signiﬁcantly between the two  age
roups. The lower chemotherapy dose for older patients, and the
ubsequent decrease in complications, might be an explanation for
his ﬁnding.
.3. Consolidation treatmentThe average costs of consolidation treatment were D 34,225 for
igh-dose chemotherapy, D 33,277 for autologous HSCT, D 44,070
or allogeneic HSCT from sibling donor and D 82,041 for allo-
eneic HSCT from MUD  (Table 3). The costs of UCB transplantation
able 3
osts of consolidation treatment (in 2010 Euros, 1 Euro = $1.3257 [16]).
High-dose
chemotherapy
(N = 47)
Au
HS
(N 
Average time (days) 100 10
Mean costs
(SE)
In-hospital stay 21,247
(914)
19
(12
Hospital visits 1477
(148)
17
(23
Diagnostic procedures 4263
(326)
55
(51
Medication 3389
(103)
30
(16
Blood  products 3848
(346)
30
(52
Radiation – – 
HLA-typing – – 
Donor search – – 
Total  mean costs
(SE)
34,225
(1366)
33
(24
Median costs 33,031 31
SCT: hematopoietic stem cell transplantation; MUD: matched unrelated donor; SE: stan
* Signiﬁcantly different from high-dose chemotherapy (p < 0.05).
† Signiﬁcantly different from autologous HSCT (p < 0.05).
‡ Signiﬁcantly different from allogeneic HSCT from sibling donor (p < 0.05).were not calculated, as only ﬁve patients received this type of
transplantation. No signiﬁcant difference in total costs was  found
between high-dose chemotherapy, autologous HSCT and allogeneic
HSCT from a sibling donor. However, some cost components dif-
fered signiﬁcantly between the treatments. The costs of diagnostic
procedures were signiﬁcantly higher during autologous HSCT and
allogeneic HSCT from a sibling donor compared to high-dose
chemotherapy. The medication costs during autologous HSCT were
signiﬁcantly lower than the medication costs during high-dose
chemotherapy. Although allogeneic HSCT from a sibling donor led
to additional costs of radiation and HLA-typing, the total costs did
tologous
CT
= 18)
Allogeneic
HSCT sibling
(N = 35)
Allogeneic
HSCT MUD
(N = 21)
6 101 128*,‡
,944
95)
17,007*,†
(2999)
18,682
(2258)
06
7)
2038*,†
(127)
2767*,† ,‡
(172)
30*
2)
8099*
(1213)
10,670*,† ,‡
(778)
50*
2)
3883
(466)
5427*,† ,‡
(566)
46
8)
1436*,†
(437)
2462*,‡
(559)
1638
(100)
1610
(140)
9968
(NA)
9968
(NA)
– 30,456
(NA)
,277
65)
44,070
(4765)
82,041* ,† ,‡
(3453)
,951 37,394 83,165
dard error; NA: not available (mean costs derived from Blommestein et al. [14,15]).
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Table  4
Costs of follow-up (in 2010 Euros, 1 Euro = $1.3257 [16]).
Preceding treatment “Younger” patients “Older”
patients
High-dose
hemotherapy
(N = 31)
Autologous
HSCT
(N = 16)
Allogeneic
HSCT sibling
(N = 31)
Allogeneic
HSCT MUD
(N = 19)
Induction
treatment
(N = 27)
Mean costs
(SE)
In-hospital stay 390
(240)
0!
(0)
7227*,† ,§
(2556)
16,687*,† ,§
(5455)
2098
(961)
Hospital visits 1794
(234)
2595
(1030)
3027*,†
(358)
4112*,† ,§
(495)
2702
(491)
Diagnostic procedures 3183
(871)
2330
(396)
8105*,† ,§
(1119)
14,395*,† ,‡ ,§
(1918)
3437
(756)
Medication 200
(26)
164*!
(58)
1651*,† ,§
(232)
2450*,† ,§
(416)
357
(87)
Blood products 287§
(184)
800
(699)
1998*,†
(678)
2822*,†
(1454)
3146
(1476)
Total mean costs
(SE)
5856
(1172)
5889
(2000)
22,008* ,† ,§
(4345)
40,468* ,† ,‡ ,§
(8299)
11,740
(3630)
Median costs 4476 3819 14,287 29,416 4214
HSCT: hematopoietic stem cell transplantation; MUD: matched unrelated donor; SE: standard error.
* Signiﬁcantly different from high-dose chemotherapy (p < 0.05).
† Signiﬁcantly different from autologous HSCT (p < 0.05).
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a‡ Signiﬁcantly different from allogeneic HSCT from sibling donor (p < 0.05).
§ Signiﬁcantly different from follow-up after induction treatment (p < 0.05).
ot signiﬁcantly differ from the costs of high-dose chemotherapy
nd autologous HSCT due to a signiﬁcantly shorter hospital stay
22.5 days compared to 29.6 and 27.8 days, respectively) and lower
lood product costs. The signiﬁcantly shorter in-hospital stay dur-
ng allogeneic HSCT from a sibling donor is likely due to outpatient
trategies in allogeneic transplantations in modern times [17]. An
llogeneic HSCT from MUD  was signiﬁcantly more expensive than
he other consolidation treatments. The higher costs were not only
elated to the costs of radiation, donor search and HLA-typing. The
osts of hospital visits, diagnostic procedures and medication were
lso signiﬁcantly higher during an allogeneic HSCT from MUD. In
ddition, the treatment duration was signiﬁcantly longer during
llogeneic HSCT from MUD  compared to high-dose chemotherapy
nd allogeneic HSCT from a sibling donor.
.4. Follow-up
The follow-up costs differed according to the preceding treat-
ent (Table 4). The average 1-year follow-up costs were D 11,740
fter induction treatment, D 5856 after high-dose chemotherapy,
 5889 after autologous HSCT, D 22,008 after allogeneic HSCT from
ibling donor and D 40,468 after allogeneic HSCT from MUD. The
ollow-up costs after allogeneic HSCTs (both from sibling donor
nd MUD) were signiﬁcantly higher than the other follow-up costs,
ainly because of higher costs of in-hospital stay, diagnostic proce-
ures and hospital visits. The average days of hospitalization during
ollow-up ranged from 0 days after an autologous HSCT to 16.6 days
fter an allogeneic HSCT from MUD.
The follow-up costs included both patients who died or relapsed
uring the ﬁrst year and patients alive without relapse. High
ollow-up costs might be caused by the high costs of patients
ho died during the ﬁrst year, because it has been shown
hat the last year before death is the most expensive period in
ne’s lifetime [18,19]. In our study, the mortality rate was sig-
iﬁcantly higher after induction treatment or allogeneic HSCT
ompared to the other treatments. Nevertheless, signiﬁcant dif-
erences in follow-up costs were still apparent when the analysis
as restricted to surviving patients. The higher follow-up costs
fter allogeneic transplantations are probably related to thetreatment of graft-versus-host disease and infections. The aver-
age number of hospital visits after allogeneic transplantations were
lower than expected according to treatment protocol, because
patients who died during follow-up had signiﬁcantly fewer hospital
visits. These patients were more frequently admitted for in-hospital
stay.
3.5. Composition of the costs of treatment
In-hospital stay accounted for 52–64% of the total costs of
chemotherapy and autologous HSCT and 24–41% of the total costs
of allogeneic transplantations. Other large cost components of allo-
geneic transplantations were HLA-typing and donor search (Fig. 1A
and B). The composition of the total follow-up costs differed accord-
ing to the preceding treatment. In general, a large part of the
follow-up costs consisted of diagnostic procedures (30–50%). The
other follow-up costs were mainly related to in-hospital stay after
an allogeneic HSCT and to costs of hospital visits after induction
treatment, high-dose chemotherapy and autologous HSCT (Fig. 1C).
4. Discussion
This study provides insight into the current costs of the initial
treatment of AML. This study shows that the treatment costs of
AML are substantial. The average costs of the initial treatment of
one AML  patient are D 117,495. Previously estimated initial treat-
ment costs were $80,030 in 1990 for younger patients and $52,048
in 1998 for older patients (respectively D 80,109 and D 59,630 in
2010 Euros) [5,6]. In a Swedish study, the treatment costs, includ-
ing relapse, of all AML  patients were 356,911 Swedish Krona in 1990
(D 74,508 in 2010 Euros) [4].  The treatment costs calculated in this
study were 43–67% higher than the previously estimated treatment
costs. The largest increase in costs was found for diagnostic proce-
dures, which increased with 80–220%. This large increase can be
explained by both the use of new diagnostic technologies like real-
time polymerase chain reaction and an increase in use of standard
diagnostic procedures.
Only a few recent studies reported costs of parts of AML
treatment. A French study estimated the total induction costs on
A. Leunis et al. / Leukemia Research 37 (2013) 245– 250 249
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fig. 1. Composition of the total costs per treatment phase. Costs were subcatego
edication, blood products, radiation, HLA-typing and donor search. (A) Induction 
 43,037 in 2005 Euros (D 46,463 in 2010 Euros) [20]. These costs
re half of the induction costs calculated in our study. However, the
rench study differs from ours with respect to the treatment pro-
ocol and methodology of cost calculation. In the French study, a
econd course was only administered to patients without a CR after
he ﬁrst course (28% of all patients, compared to 83% in our study).
n addition, costs of outpatient visits and related diagnostic proce-
ures were excluded in the French study. These costs accounted for
bout 2.6% of the total costs per induction course in our study. The
osts of sibling transplantations in our study were comparable with
he costs estimated by Cordonnier et al. [21], which were D 64,600
fter high-dose conditioning (HDC) and D 60,000 after reduced-
ntensity conditioning (RIC) in 2001 Euros, respectively (D 75,718
nd D 69,980 in 2010 Euros).
It was not feasible to distinguish between HDC and RIC for allo-
eneic HSCT in our study. In the literature, some disagreement
xists regarding differences in treatment costs between these con-
itioning regimens. Cordonnier et al. [21] did not ﬁnd signiﬁcant
ifferences in costs, while Saito et al. [22] found signiﬁcant lower
ransplantation costs after RIC due to a shorter hospital stay. The
horter hospital stay might also be related to the stem cell source.
eripheral blood transplants were signiﬁcantly more administered
n patients receiving RIC [22]. As it has been shown that the hospital
tay is shorter for patients receiving peripheral blood transplants
5], we do not expect that the type of conditioning has a large impact
n treatment costs.
This study was a retrospective study with resource use collected
rom registered data. Due to the unavailability of data regarding thein the following subgroups: in-hospital stay, hospital visits, diagnostic activities,
ent cost, (B) consolidation treatment costs and (C) follow-up costs.
start and end of treatment phases, the total period after hospitaliza-
tion was  deﬁned as preparation of the following treatment phase.
It is not expected that this deﬁnition will have large impact on the
calculated costs, because the costs between treatment phases were
relatively low.
In our study relapse costs were excluded because only a small
proportion of patients experienced a relapse in the available follow-
time. It is expected that inclusion of relapse costs would especially
increase the costs after high-dose chemotherapy and autologous
HSCT, because the risk of relapse is higher after these treatments
compared to allogeneic HSCT [23].
In general, in-hospital stay was the major cost driver in
the treatment of AML. The main reason for the long hospi-
tal stay is that patients remain hospitalized until blood count
recovery to avoid infections and bleeding. Several studies have
shown that outpatient management after treatment is safe and
feasible for a selection of patients [24,25]. Outpatient manage-
ment would not only reduce costs, but might also improve
the quality of life of patients. Studies including more patients
are warranted to investigate whether the hospital stay can be
reduced without a negative impact on survival and quality of
life.
The main objective of this study was  to calculate costs of initial
treatment of AML  irrespective of patient characteristics. In addi-
tion, the costs of different treatment protocols were compared.
As patients were not randomized between treatments, we can-
not guarantee the comparability of the patients receiving different
treatments. However, we do not expect large difference in patient
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haracteristics, since treatment choice is mainly determined by the
vailability of a suitable donor. Additional analyses support this
ssumption as no signiﬁcant differences in age were found between
he post-remission treatments.
The results of this study can support hospitals in their nego-
iations with health insurers to receive adequate reimbursement
or the treatment costs. Some concerns might exist regarding the
ransferability of the calculated costs to other countries. Although
he included patients were only treated in the Netherlands, these
atients were treated according to international guidelines [26].
urther studies should investigate whether the costs of the second
nduction course differs between patients who achieved a CR after
he ﬁrst cycle or not. In addition, unit prices might differ between
ountries. However, a comparison of the costs with other recent
ost calculations showed comparable results [20,21].
The calculated costs are representative estimates of current
reatment costs, because resource use was derived from a sufﬁcient
umber of patients treated according to current treatment proto-
ols in several hospitals. Our results show large cost differences
etween the post-remission treatment options for AML  patients.
hese differences should also be considered in treatment guide-
ines. While the effectiveness of AML  treatments is established in
andomized controlled trials, the cost-effectiveness is not always
etermined. Combining our results to current and future effective-
ess studies might help to determine whether beneﬁts of allogeneic
SCT outweigh the higher treatment costs.
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